The original research group evaluated the effect of rapamycin on CD4 + CD25 + Foxp3 + Tregs in RA patients, suggesting that rapamycin can promote the proliferation of Tregs in low-activity RA patients, thereby balancing Th17/Tregs. This evidence concerns the gene CD4 and rheumatoid arthritis.